Trilogy Capital’s Eli Lilly LLY Stock Holding History

Trilogy Capital’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.14M	Buy	5,952 +516	+9%	+$527K	0.28%	65
2026 Q1	$5M	Buy	5,436 +434	+9%	+$440K	0.22%	71
2025 Q4	$5.38M	Buy	5,002 +316	+7%	+$302K	0.24%	66
2025 Q3	$3.58M	Buy	4,686 +499	+12%	+$371K	0.17%	95
2025 Q2	$3.26M	Buy	4,187 +2,963	+242%	+$2.3M	0.16%	94
2025 Q1	$1.01M	Sell	1,224 -59	-5%	-$49.1K	0.05%	173
2024 Q4	$991K	Sell	1,283 -64	-5%	-$53K	0.05%	178
2024 Q3	$1.19M	Buy	1,347 +51	+4%	+$45.9K	0.06%	168
2024 Q2	$1.17M	Buy	1,296 +900	+227%	+$720K	0.06%	161
2024 Q1	$308K	Buy	+396	New	+$282K	0.02%	250
2018 Q4	–	Sell	-47	Closed	-$5K	–	384
2018 Q3	$5K	Hold	47	–	–	﹤0.01%	402
2018 Q2	$4K	Hold	47	–	–	﹤0.01%	392
2018 Q1	$4K	Buy	+47	New	+$3.78K	﹤0.01%	330

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

ONB

Old National Bancorp Evansville, Indiana $5.02B AUM 25.65% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

GIM

Goelzer Investment Management Carmel, Indiana $2.29B AUM 39.12% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Trilogy Capital's LLY Position: Q2 2026 in Review

Trilogy Capital increased its Eli Lilly (LLY) stake by 9.5% in Q2 2026, buying an estimated $527K and bringing the position to 5,952 shares worth $7.14M. The position accounts for 0.28% of the portfolio, ranked #65.

Trilogy Capital first reported a position in LLY in Q1 2018 and has held it in 13 quarters since. 1,692 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

Trilogy Capital held 5,952 shares of Eli Lilly worth $7.14M as of Q2 2026.
Trilogy Capital bought 516 Eli Lilly shares in Q2 2026, an estimated $527K.
Eli Lilly made up 0.28% of Trilogy Capital's portfolio in Q2 2026, its #65 holding.
Trilogy Capital first reported a position in Eli Lilly in Q1 2018 and has held it in 13 quarters since.
1,692 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Trilogy Capital's 13F filing for Q2 2026, filed 6 Jul 2026.